Is Biofrontera Inc. Warrants (BFRIW) overvalued? · rev $37.3M
Biofrontera Inc. Warrants (BFRIW) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Biofrontera Inc. Warrants (BFRIW) looks expensive on cached numbers — not a short thesis.
Latest reported BFRIW revenue for 2024-12-31 was $37.3M. Net income was -$17.8M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. BFRIW currently screens at market cap $0.
BFRIW currently screens at market cap $0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BFRIW 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BFRIW stock page for the full model, not this heading.
Not investment advice.